Floatz Rating
B60/100
Confidence
Indicative
Sponsor
Merck Sharp & Dohme LLC
Modality
Small molecule
Development Phase
Phase 2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
47High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT00537017CT.gov Follow Up Safety Study of SCH 420814 in Subjects With Parkinson's Disease (P05175) | — | Completed | — | — | — |
NCT00406029CT.gov Dyskinesia in Parkinson's Disease (Study P04501) | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Brain Disorder
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Levodopa (this asset) | Merck Sharp & Dohme LLC | P2 | B · 60 |
| Galantamine Hydrobromide | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | P3 | B |
| Live Combined Bifidobacterium | Beijing Friendship Hospital | P4 | B |
| Fremanezumab | Hospital Clínico Universitario de Valladolid | P4 | B |
| Donanemab | Eli Lilly and Company | P3 | B |
| Live Combined Bifidobacterium,Lactobacillus And Enterococcus Capsules | Beijing Friendship Hospital | P4 | B |
| Tocilizumab | Zhujiang Hospital | P3 | B |
| Physiologic Sodium Chloride Solution | Zhujiang Hospital | P3 | B |
| Tenecteplase | University of Melbourne | P2/3 | B |
+33 more in the Brain Disorder cohort
Other indications for Levodopa
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Drug-Induced Dyskinesia | — | P4 | A · 80 |
| Parkinson Disease | — | P4 | BBB · 74 |
| Movement Disorder | — | P4 | BBB · 74 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- Galantamine HydrobromideJohnson & Johnson Pharmaceutical Research & Development, L.L.C.B
- Live Combined BifidobacteriumBeijing Friendship HospitalB
- FremanezumabHospital Clínico Universitario de ValladolidB
- DonanemabEli Lilly and CompanyB
- Live Combined Bifidobacterium,Lactobacillus And Enterococcus CapsulesBeijing Friendship HospitalB
Citation
Floatz Terminal. Levodopa in Brain Disorder. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/levodopa-brain-disorder
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →